ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 156 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2017. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $25,000 | +212.5% | 180 | +69.8% | 0.00% | +200.0% |
Q3 2018 | $8,000 | -55.6% | 106 | -55.1% | 0.00% | -50.0% |
Q2 2018 | $18,000 | +80.0% | 236 | +55.3% | 0.00% | 0.0% |
Q2 2017 | $10,000 | +11.1% | 152 | +15.2% | 0.00% | 0.0% |
Q1 2017 | $9,000 | -10.0% | 132 | -1.5% | 0.00% | -33.3% |
Q4 2016 | $10,000 | – | 134 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |